HR 9169 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To support polycystic kidney disease research, and for other purposes.
Summary
The PKD Cures Act would expand research activities at the National Institutes of Health focused on polycystic kidney disease, including basic research on the disease's genetic mechanisms, translational research to identify potential treatments, and clinical trials. The bill requires the NIH to collaborate with other federal agencies, academic institutions, and private organizations to accelerate the development of treatments and cures, and to support training programs for PKD researchers and clinicians. The bill establishes a working group tasked with developing a comprehensive research roadmap for PKD, which must identify research gaps and recommend strategies for public-private sector collaboration. The working group must include experts in nephrology and genetics as well as representatives from patient advocacy organizations. The working group must submit a report to Congress within 24 months with its findings and a plan for incorporating artificial intelligence and precision medicine into PKD research and care.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
7 cosponsors
Money behind the sponsor
Top reported contributors to Debbie Wasserman Schultz’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- LEON MEDICAL CENTERS $21,500
- NULL $19,500
- THE HAGGARD LAW FIRM $13,200
- TREMONT PARTNERS $13,200
- LIBRA GROUP $13,200
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Debbie Wasserman Schultz → · Outside spending →
Actions (2)
- Jun 4, 2026 Referred to the House Committee on Energy and Commerce. · house
- Jun 4, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
June 4, 2026
Ms. Wasserman Schultz (for herself, Mrs. Miller of West Virginia, Mr. Cleaver, and Mr. Bacon) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To support polycystic kidney disease research, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “PKD Cures Act”.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Polycystic kidney disease (in this section referred to as “PKD”) is one of the most common life-threatening genetic diseases, affecting approximately 500,000 Americans and millions worldwide.
(2) PKD leads to end-stage renal disease, or kidney failure, in the majority of affected individuals, necessitating dialysis and transplantation.
(3) More than 5 percent of patients enrolled in the Medicare End-Stage Renal Disease program have kidney failure caused by cystic kidney disease, primarily PKD.
(4) End-stage renal disease and kidney failure attributable to cystic kidney diseases, like PKD, cost Medicare an estimated $3,000,000,000 annually.
SEC. 3. EXPANSION OF NIH RESEARCH ON POLYCYSTIC KIDNEY DISEASE.
Subpart 3 of part C of title IV of the Public Health Service Act (42 U.S.C. 285c et seq.) is amended by adding at the end the following:
“SEC. 434B. EXPANSION OF NIH RESEARCH ON POLYCYSTIC KIDNEY DISEASE.
“(a) Research Focus.—The Director of the Institute shall expand and intensify research activities regarding polycystic kidney disease (in this section referred to as ‘PKD’), including—
“(1) basic research to understand the genetic and molecular mechanisms of PKD;
“(2) translational research to identify biomarkers and potential therapeutic targets; and
“(3) clinical research to evaluate the safety and efficacy of new and existing treatments.
“(b) Collaboration.—In implementing the requirements of subsection (a), the Director of the Institute shall—
“(1) collaborate with other Federal agencies, academic institutions, and private sector stakeholders to accelerate the development of treatments and cures; and
“(2) support training programs to cultivate a workforce of researchers and clinicians specializing in PKD.
“(c) Priority.—In implementing the requirements of subsection
(a), the Director of the Institute shall prioritize research proposals that demonstrate a clear potential to advance understanding and treatment of PKD.
“SEC. 434C. DEVELOPMENT OF COMPREHENSIVE PKD ROADMAP.
“(a) In General.—The Director of NIH shall establish a working group to develop a comprehensive roadmap for polycystic kidney disease (in this section referred to as ‘PKD’) research and innovation.
“(b) Membership.—The Director of NIH shall appoint the members of the working group, who shall be—
“(1) experts in nephrology, human genetics, or molecular and cellular biology with expertise in the mechanistic pathways of PKD;
“(2) representatives of PKD patient advocacy organizations; or
“(3) such other stakeholders as the Director determines appropriate.
“(c) Responsibilities.—In developing the comprehensive roadmap referred to in subsection (a), the working group shall—
“(1) identify research gaps and priorities;
“(2) recommend strategies to enhance collaboration between the public and private sectors;
“(3) propose timelines and benchmarks for achieving key milestones in PKD innovation; and
“(4) develop a plan for integrating new technologies, such as artificial intelligence and precision medicine, into PKD research and care.
“(d) Report.—Not later than 24 months after the date of enactment of this section, the working group shall submit to Congress a report detailing the findings and recommendations of the working group, including the comprehensive roadmap referred to in subsection (a).”. <all>
Comments